AZ Sint-Lucas Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial
2010
NCT01308021
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

AZ Sint-Lucas | AZ Sint-Lucas Gent

Active Ingredients

Drugs in Phase 2 Trials (3)

lolium perenne pollen (1 trial)

nivolumab (opdivo) (1 trial)

pembrolizumab (keytruda) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 2)

Carcinoma, Renal Cell (Phase 2)

Carcinoma, Transitional Cell (Phase 2)

Rhinitis, Allergic, Seasonal (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 3